YouTube · Q2 2026 · 2026-07-31
MRK · NYSE
Merck & Co.
Drug Manufacturers - General · United States
USD 146.87-0.2% daily changeQuote 2026-09-18 · USD
- Market cap (USD)
- US$362.35B
- Trailing P/E
- 117.50x
- Forward P/E
- 15.38x
- Quarterly revenue growth
- 5.1%
- Trailing net margin
- 4.8%
- Indicated dividend yield
- 2.3%
Snapshot 2026-09-20 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Next earnings: 2026-10-29 (provider estimate, not issuer-confirmed).
Company background
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Company websiteQ1 2026
Go beyond the headline.
Comparable businesses
MRK peer comparison
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
| Metric | MRKMerck & Co., Inc.Snapshot 2026-09-20Financial period: 2026-06-30 | ABBVAbbVie Inc.Snapshot 2026-09-20Financial period: 2026-06-30 | NVSNovartis AGSnapshot 2026-09-20Financial period: 2026-06-30 | Peer medianSimilar-size peers only |
|---|---|---|---|---|
| Market capMarket value, converted to USD | US$362.35B | US$466.45B | US$266.80B | US$366.63Bn=2 |
| Forward P/EProvider forward earnings estimate | 15.38x | 16.23x | 14.27x | 15.25xn=2 |
| EV / EBITDAEnterprise value / trailing EBITDA | 14.17x | 17.25x | 13.36x | 15.31xn=2 |
| Revenue growthLatest quarter vs prior-year quarter | 5.1% | 10.2% | 0.8% | 5.5%n=2 |
| Operating marginLatest reported quarter | -0.2% | 40.0% | 34.6% | 37.3%n=2 |
| Free cash flow yieldTrailing cash flow / market cap | 4.2% | 3.6% | 4.5% | 4.0%n=2 |
| Net debt / EBITDANet debt / trailing EBITDA | 1.62x | 2.09x | 1.79x | 1.94xn=2 |
| Debt / equityTotal debt / positive book equity | 1.28x | — | 1.17x | — |
| Trailing P/ETrailing twelve-month earnings | 117.50x | 74.56x | 21.17x | 47.87xn=2 |
| Price / bookPrice / positive book equity per share | 8.65x | — | 6.42x | — |
| EV / salesEnterprise value / trailing revenue | 6.15x | 8.24x | 5.44x | 6.84xn=2 |
| Earnings growthLatest quarter vs prior-year quarter | — | 290.4% | -17.0% | 136.7%n=2 |
| Gross marginTrailing twelve months | 75.9% | 72.8% | 75.0% | 73.9%n=2 |
| Net marginTrailing twelve months | 4.8% | 9.8% | 22.5% | 16.2%n=2 |
| Return on equityProvider trailing return; positive equity only | 7.0% | — | 30.3% | — |
| Free cash flow marginTrailing free cash flow / revenue | 22.8% | 26.2% | 21.0% | 23.6%n=2 |
| Dividend yieldIndicated annual dividend / price | 2.3% | 2.6% | 3.4% | 3.0%n=2 |
| Earnings payoutProvider trailing dividend payout | 268.8% | 190.4% | 71.6% | 131.0%n=2 |
| Current ratioCurrent assets / current liabilities | 1.32x | 0.81x | 0.86x | 0.84xn=2 |
| BetaProvider historical market sensitivity | 0.23 | 0.28 | 0.49 | 0.39n=2 |
YouTube · Q2 2026 · 2026-07-31
YouTube · Q2 2026 · 2026-07-21
Comparison methodology & limitations
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Financial trends
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Revenue
Reported figures
Financial data & calculation notes
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Valuation & price history
Adjusted closing price
Price history loads separately.
Price figures
Earnings-multiple scenario
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-09-20. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Research history for MRK
Q1 20262026-05-01
MRK Stock: Q1 2026 Earnings Analysis
Presentation · 2026-05-01 · YouTube
MRK Q1 2026 earnings analysis
Presentation · 2026-04-09 · YouTube